oral glp-1 inhibitor Orforglipron, an Small-Molecule Receptor Agonist, in Early Type 2 Diabetes Novo Nordisk's oral GLP-1 drug

More than appetite support

GLP-1 receptor agonist use appeared linked to significantly reduced all-cause mortality among people with sickle cell disease, according to study results presented at ASH Annual Meeting and Exposition.People who used the medications also exhibited reduced risk for other adverse outcomes, including sickle cell crisis, venous thromboembolism, ischemic stroke or transient ischemic

Sleep disturbances affect up to 30% of people starting GLP-1 therapy

Considering IVY RX for weight loss

Formulated without dairy, soy, gluten, wheat, peanuts, tree nuts, eggs, fish, shellfish, artificial sweeteners, or preservatives

The FDA lawfully determined that Eli Lilly &amp